Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be untreatable, for up to one year.

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

High levels of a chemical that is believed to be behind sudden and inexplicable heart attacks and strokes could soon have ...

One in four patients who present with elevated low-density lipoprotein cholesterol levels have no documented use of statin therapy, according to a study published April 16 in Epic Research.  Here are ...

An estimated 64 million Americans have elevated levels of lipoprotein(a), or Lp(a), a type of cholesterol that can increase the risk of heart attack and other cardiovascular problems. Having high ...

A new study published in the recent issue of Atherosclerosis journal showed that lipoprotein(a) [Lp(a)] levels may change the ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...